Board of Directors

Louis J Nisbet D.Sc, Non Executive Chairman

Louis is an experienced Health Industries professional who operated at senior levels in Roche, Glaxo and SmithKline from 1974 to 1987. Between 1987 and 2001 he was a successful serial entrepreneur, setting up or building a number of biopharmaceutical, life sciences and pharmaceutical service businesses, of which 3 achieved profitable exits with the others continuing to trade. From 1999 to 2008 he was Partner and Director of private equity firm Sitka Partners and between 2002 and 2007 he was a Director of the Sitka/Noble Health Fund VCT plc, a quoted Investment fund. Sitka was sold to Noble Group in 2005 and three years later Louis left to set up VivaNova Ltd, to work more closely with growth companies and companies undergoing change or M&A. His considerable Board experience (15 Directorships and 5 investor monitoring) spans executive and non-executive appointments for quoted and unquoted companies, including CEO of Xenova PLC, Chairman of Brax Group PLC and eCare International PLC, and Non Executive Director (Amura Therapeutics Ltd, Altrix Healthcare Ltd, Omnidental Sciences Ltd, Onyx Scientific Ltd, Optasia Medical Ltd). He has lead new issues and secondary fundraisings in public and private businesses. The companies include service providers, diagnostics, devices, therapeutics, specialty pharma and fund management. Louis has an extensive international network providing access across financial, industrial, R&D, academic and service sectors. He was the first recipient of the Ernst & Young European Biotechnology Entrepreneur of the Year award.

He has FSA (UK Financial Services Authority) Approved Person status.

David Scales, CEO

David has more than 20 years experience in large pharmaceutical companies, having held a senior international position in research and development within GlaxoWellcome with staff in USA, UK, Italy and Japan. He moved into the biotechnology sector in 2000 working as R&D director for Strakan Ltd (now ProStrakan Group), Charterhouse Therapeutics Ltd and Antisoma PLC before becoming CEO of Cerogenix Ltd. He was a non-executive director of BIBRA International, Enhance Biotech Inc, sat on the board of the UK Public Health Laboratory Service and has been a consultant in the life sciences practice of Spencer Stuart. He joined Glycoform as CEO in 2008.

David earned three degrees from London University and the Royal Postgraduate Medical School. He was awarded a Fellowship of the Royal College of Pathologists in 1993 and an LLM from the Cardiff Law School in 1995. He held visiting chairs at King's College and the School of Pharmacy at London University.

Landon T. Clay, Non-Executive Director

Landon is a Managing Member of East Hill Advisors, Chairman of the Clay Mathematics Institute, and Chairman of the Caribbean Conservation Corporation. Prior to founding East Hill, he was CEO and Chairman of Eaton Vance. Landon serves on various other boards including the Museum of Fine Arts, Boston. He received an AB cum laude, from Harvard College.

James Mallinson, Non-Executive Director

James joined Isis in April 2003 to manage the equity stakes in spin-out companies held by the University which are now part of Oxford Spin-out Equity Management. Prior to this, he worked in the private equity group at Abbey National Treasury Services where he was responsible for technology investments. James gained his MBA from Cranfield in 1990 and has over ten years' experience in venture capital as both investor and adviser. James gained his first degree in Engineering Science at the University of Oxford, following which he trained and worked as a software engineer, initially with Marconi Underwater Systems.

Elizabeth Phelps for ZWM Ltd, Company Secretary

Elizabeth Phelps founded ZWM Ltd in 1999, since when she has been providing commercial, financial and company secretarial services, including assisting in financing rounds. Prior to that she held various general management positions in AEA Technology (a contract research and development company) latterly specializing in acquisitions and disposals, and served as director and company secretary to a number of subsidiaries. She graduated from Warwick University and went on to complete an MA in comparative literature at the University of East Anglia.